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Abstract 
Background: Antitumor compounds PM100117 and PM100118 are glycosylated polyketides derived from the 
marine actinobacteria Streptomyces caniferus GUA-06-05-006A. The organization and characterization of the 
PM100117/18 biosynthesis gene cluster has been recently reported.
Results: Based on the preceding information and new genetic engineering data, we have outlined the pathway by 
which PM100117/18 are glycosylated. Furthermore, these genetic engineering experiments have allowed the genera-
tion of novel PM100117/18 analogues. Deletion of putative glycosyltranferase genes and additional genes presum-
ably involved in late biosynthesis steps of the three 2,6-dideoxysugars appended to the PM100117/18 polyketide 
skeleton, resulted in the generation of a series of intermediates and novel derivatives.
Conclusions: Isolation and identification of the novel compounds constitutes an important contribution to our 
knowledge on PM100117/18 glycosylation, and set the basis for further characterization of specific enzymatic reac-
tions, additional genetic engineering and combinatorial biosynthesis approaches.
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Background
Natural products (NPs) are an invaluable source of bio-
logically active drugs with therapeutic significance [1, 2]. 
A considerable portion of these products present as part 
of their chemical structure deoxysugar (DOH) moieties, 
mainly 6-deoxyhexoses (6DOH) and 2,6-dideoxyhex-
oses (2,6DOH) [3, 4]. Many studies aimed to unravel the 
structure–activity relationship of numerous NPs have 
shown the relevant and diverse functional roles played by 
DOHs on a wide range of biological activities, including 
antibiotic, antifungal, antitumor and antiparasitic [5–8]. 
In accordance with these important roles, removal of 
DOH moieties might lead to various degrees of reduction 
in activity, ranging from a complete activity loss to the 
retention of certain activity level as the glycosidic frac-
tion is eliminated [4].
Glycobiology research has led to discover and deline-
ate the biosynthesis pathway of many natural sugars [9]. 
As a result, a core set of enzymatic activities has been 
found to synthesize the diverse sugar structures observed 
in nature. Various common enzyme reactions, which 
include deoxygenations, transaminations, ketoreduc-
tions, C-, N- or O-methylations, epimerizations, and less 
frequently oxygenations, are required to generate the 
surprisingly high structural diversity of natural DOHs 
[3, 9]. The complete enzyme set required for DOH bio-
synthesis is, in most cases, encoded in the biosynthesis 
gene cluster of the respective NP. Therefore, because 
the great majority of sugars present in bioactive NPs are 
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DOHs, identification of clusters containing genes coding 
for these activities may constitute a useful strategy for 
the discovery of clinical attractive drugs [10, 11]. Some 
of these enzymes have been thoroughly characterized 
in vitro [12–14] and in vivo [15] in multiple attempts to 
modify sugar structures and alter the glycosylation pat-
tern of NP. Upon DOHs biosynthesis, transfer onto 
specific positions of the corresponding aglycone is con-
trolled by glycosyltransferase (GT) enzymes. These 
enzymes require an activated DOH donor, typically a 
NDP or NMP-DOH, for transfer of the glycosyl residue 
to the acceptor molecule [16]. In this way, a staggering 
diversity of sugars can be transferred to a no less struc-
turally diverse array of acceptor molecules, including 
polyketide, nonribosomal peptide, indolocarbazole and 
aminocoumarin aglyca among many others, by the vari-
ous hundreds of putative GTs described in databases as 
involved in NPs biosynthesis [16] (http://www.cazy.org/
GlycosylTransferases.html). Most GTs catalyze O-glyco-
sidic bond formation between the sugar and its natural 
aglycone. Other linkages such as C–C [17] or C–N [18] 
glycosidic bonds are relatively unusual. Substrate flex-
ibility is an interesting feature of some sugar biosynthe-
sis and GT enzymes. This is especially remarkable in 
GTs which can show different degrees of promiscuity 
towards the acceptor and/or the donor molecules [3, 8, 
19, 20]. Similarly, other GTs possesses the unusual abil-
ity to transfer sugars to different positions of the same 
aglycone sometimes using different type of linkages [21, 
22]. GT flexibility is a key aspect for the success of many 
glycosylation pattern engineering strategies aimed to 
afford and develop new NPs. Deletion and heterologous 
expression of DOH biosynthesis and/or GTs genes have 
allowed the generation of a handful of interesting deriva-
tives from structurally diverse NPs, such as erythromy-
cin [23], methymicin/pikromycin [24], daunorubicin/
doxorubicin [25], rebeccamycin [26] or elloramycin 
[27–29], among others. In some cases, novel derivatives 
resulting from these strategies show an enhanced bioac-
tivity and/or improved pharmacological properties. Rel-
evant examples of glycosylation-pattern modifications 
leading to these improvements are the aureolic acids 
demycarosyl-3D-β-d-digitoxosyl-mithramycin SK, 
demycarosyl-mithramycin SDK and demycarosyl-3D-β-
d-digitoxosyl-mithramycin SDK, which derived from the 
clinically used anticancer agent mithramycin by combi-
natorial biosynthesis in Streptomyces argillaceus [30].
PM100117 and PM100118 are glycosylated macrolides 
produced by the marine actinobacteria Streptomyces 
caniferus GUA-06-05-006A [31, 32]. The glycosyla-
tion pattern of PM100117/18 consists of three 2,6DOHs 
(l-axenose, 2-deoxy-l-fucose and l-rhodinose), which 
along with a naphthoquinone chromophore form a 
side chain attached to the PM100117/18 polyketide 
skeleton (Fig.  1a). The remarkable antitumor activ-
ity of PM100117/18, and the generation of structural 
analogues with improved bioactivity recently reported 
[32], prompted us to undertake the engineering of these 
compounds looking for more derivatives. Here, we 
describe the generation of seven novel analogues by a 
glycoengineering approach consisting in the deletion of 
PM100117/18 biosynthetic genes previously character-
ized in silico as coding for putative GTs and key sugar 
biosynthetic enzymes (Fig. 1b). In addition, the outcome 
of these genetic engineering manipulations provided 
valuable information on the PM100117/18 glycosylation 
steps.
Results
Deletion of 2,6‑dideoxysugar biosynthesis genes
The PM100117/18 gene cluster encodes most of the puta-
tive functions required to catalyze the biosynthesis of the 
three 2,6DOH moieties appended to the PM100117/18 
macrolactone ring (Fig.  1). From these activities, as 
deduced in silico (Additional file  1), biosynthesis of 
l-axenose, 2-deoxy-l-fucose and l-rhodinose can be 
envisaged to occur as depicted in Fig. 2. Early biosynthe-
sis steps of 6DOHs involves intermediacy of nucleoside 
diphosphate (NDP)-4-keto-6DOH, which is synthesized 
from a hexose-1-phospate, most possibly d-glucose, in 
two reaction steps catalyzed by a NDP-d-hexose syn-
thase (GonGS) and a NDP-d-hexose-4,6-dehydratase 
(GonD2), respectively. To achieve, 2-deoxy-l-fucose and 
l-rhodinose, NDP-4-keto-6DOH could be converted into 
a NDP-4-keto-2,6DOH intermediate with an equatorial 
hydroxyl group at carbon C3, by the sequential activity 
of NDP-d-hexose-2,3-dehydratase (GonD1) and NDP-
d-hexose-3-ketoreductase (GonR3), in accordance with 
the high resemblance of GonR3 to other 3-ketoreduc-
tases that render this configuration (Additional file  1). 
Similarly, l-axenose biosynthesis would involve a NDP-
4-keto-2,6DOH intermediate with a hydroxyl group at 
carbon C3 in axial stereo configuration, however the 
corresponding NDP-d-hexose-3-ketoreductase is not 
present in the PM100117/18 gene cluster. Later steps 
towards PM100117/18 DOHs biosynthesis from this key 
2,6DOH intermediate might involve four reaction types 
outlined in Fig.  2, which include C-methylation at C3 
(GonCM), 3-deoxygenation (GonD3), 5- or 3,5-epimeri-
zation (GonE) and 4-ketoreduction (GonR1/GonR2).
Herein, we sought to generate PM100117/18 struc-
tural analogues by manipulating the biosynthesis of their 
pendant 2,6DOHs. For that purpose we generated the 
mutant strains ΔgonCM, ΔgonD3, ΔgonE, and ΔgonR1, 
in which genes involved in late steps of 2,6DOH bio-
synthesis, gonCM, gonD3, gonE, and gonR1, respectively, 
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were deleted. To detect the biosynthesis of PM100117/18 
derivatives, whole-culture extracts from these strains 
were analyzed by UPLC (Fig.  3) and HPLC/MS. UPLC 
chromatograms from strains ΔgonCM, ΔgonD3 and 
ΔgonE showed suppression of PM100117 (1, UPLC 
Rt = 5.182 min, m/z 1601.9 [M + Na]+) and PM100118 
(2, UPLC Rt = 5.536 min, m/z 1585.9 [M + Na]+) biosyn-
thesis, and the appearance of several peaks correspond-
ing to potential analogues (Fig. 3a). Mass assessments by 
HPLC/MS suggested that the novel compounds detected 
in ΔgonCM are compatible with PM100117/18 analogues 
in which the first sugar moiety, l-axenose, has been 
substituted for either 2-deoxy-l-fucose or l-rhodinose. 
This was confirmed by elucidating the chemical struc-
ture of products 3 [UPLC Rt  =  6.035  min, m/z 1571.9 
(M  +  Na)+] and 4 [UPLC Rt  =  6.102  min, m/z 1555.9 
(M + Na)+] by NMR, showing that both are PM100118 
derivatives with an l-rhodinose unit in place of l-axenose 
as first sugar moiety (Fig. 3b and Additional file 2: Fig. S1 
and Table S1). The presence of a hydroxyl group at C18 
of the polyketide ring in 3 (absent in 4 and also in 1 and 
2) suggests that compound 3 might be a shunt product of 
PM100117/18 biosynthesis after undergoing a hydroxyla-
tion reaction at this position. These results are consistent 
with the involvement of GonCM in l-axenose biosynthe-
sis (Fig. 2). Likewise, compound 5 [UPLC Rt = 4.941 min, 
m/z 1487.8 (M  +  Na)+], produced by strain ΔgonD3 
(Fig. 3a), was also purified and subjected to NMR analysis 
(Additional file 2: Fig. S1 and Table S2), confirming that, 
as expected from the hypothetical 2,6DOH biosynthetic 
pathways outlined in Fig.  2, this product structurally 
derives from PM100117 by lacking the third sugar moi-
ety, l-rhodinose. The estimated molecular mass for com-
pounds 6 [UPLC Rt =  5.721  min, m/z 297 (M +  Na)+] 
and 7 [UPLC Rt = 5.796 min, m/z 239 (M + Na)+] from 
strain ΔgonE was strikingly low in comparison to that of 
the parental products, suggesting that these compounds 
might not be related to PM100117/18 biosynthesis. How-
ever, structure elucidation (Additional file 2: Fig. S1 and 
Table S3) revealed that 6 corresponds to the naphthoqui-
none chromophore, while 7 is the precursor of 6 to which 
a propionate side chain is incorporated (Fig. 3b). Masses 
displayed by compounds 8 [UPLC Rt =  6.012  min, m/z 
1457.8 (M  +  Na)+] and 9 [UPLC Rt  =  6.098  min, m/z 
1441.8 (M +  Na)+], fitted with PM100117 lacking both 
l-rhodinose as third sugar moiety and oxygenations at 
C16 and/or C17. Nonetheless, neither these structural 
features nor the configuration of the sugar moieties pre-
sumably present in 8 and 9 have been further confirmed 
because the low production level and high instability of 
these products, which made impossible the purification 
of quantities suitable for NMR analysis. On the other 
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Fig. 1 PM100117 and PM100118 2,6-DOH moieties and biosynthesis gene cluster. a PM100117/18 chemical structure. DOH moieties are indicated: 
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hand, mutant ΔgonR1 produced PM100117/18 at similar 
levels to those observed in wild type S. caniferus GUA-
06-05-006A (Fig.  3a), indicating that this gene is not 
essential for PM100117/18 2,6DOHs biosynthesis. It is 
important to note the presence in the PM100117/18 gene 
cluster of an additional putative NDP-4-keto-6-deox-
yhexose reductase gene, gonR2 (Fig. 1b). We set to deter-
mine whether this gene codes for the 4-ketoreductase 
activity presumably involved in the final biosynthesis step 
of the three PM100117/18 2,6DOHs (Fig.  2). Neverthe-
less, after recurrent attempts, we fail to produce a gonR2 
deletion mutant. As an alternative approach, gonR2 was 
cloned under the control of the ermE*p promoter to 
produce pCgonR2, which was introduced in S. caniferus 
GUA-06-05-006A. The metabolic profile of the resultant 
strain, OEgonR2, was then analyzed by UPLC, showing 
no differences with respect to wild type strain, GUA-
pSETH, carrying the respective empty plasmid (Addi-
tional file 3: Fig. S2).
Deletion of glycosyltransferase genes
The PM100117/18 biosynthesis gene cluster contains 
four ORFs (gonG1, gonG2, gonG3 and gonG4) cod-
ing for putative GT proteins [32], each of which might 
be involved in transfer of at least one DOH moiety 
to a defined position of PM100117/18. As additional 
route to produce PM100117/18 structural analogues, 
we pursued to manipulate 2,6DOH transfer to the 
PM100117/18 macrolactone aglycone by independently 
deleting these putative GT genes. Thus, we produced 
mutant strains ΔgonG1, ΔgonG2, ΔgonG3 and ΔgonG4. 
Metabolite production of these strains was examined 
as described above. It is known that loss of the naph-
thoquinone chromophore unit causes a shift in the 
PM100117/18 maximum absorption wavelength from 
254 to 216 nm [32]. Thereby, since deletion of GT genes 
could lead to glycosylation pattern changes involv-
ing loss of this structural element, screening for novel 
derivatives entailed the analysis of chromatograms at 
both wavelengths. Deletion of gonG1 or gonG2 abol-
ished PM100117/18 production (Fig.  4a) and induced 
the accumulation of various potential analogues with 
a maximum absorption wavelength at 216  nm, hence 
lacking the naphthoquinone moiety (Fig.  4b). HPLC/
MS analysis showed that novel compounds produced by 
strain ΔgonG1 possess masses corresponding to different 
variations of the PM100117/18 non-glycosylated agly-
cone, while masses of those produced by mutant strain 
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Fig. 3 Production of PM100117 (1) and PM100118 (2) derivatives 3–9 in 2,6-DOH biosynthesis gene mutant strains. a UPLC analysis (254 nm) of 
metabolite production in S. caniferus GUA-06-05-006A wild-type and ΔgonCM, ΔgonD3, ΔgonE and ΔgonR1 deletion mutants. NR: peak non-related 
to PM100117/18. b Chemical structure of various PM100117/18 analogues
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ΔgonG2 matched putative PM100117/18 analogues 
lacking the second 2,6DOH moiety. Structural elucida-
tion by NMR (Additional file 2: Fig. S1 and Table S4 and 
S5) revealed that compound 10 (UPLC Rt =  3.808  min, 
m/z 957.6 [M  +  Na]+) from ΔgonG1 indeed corre-
sponded to the PM100117/18 aglycone, while 11 (UPLC 
Rt =  3.842 min, m/z 1102.4 [M + Na]+) and 12 (UPLC 
Rt  =  3.905  min, m/z 1117.7 [M  +  Na]+) from strain 
ΔgonG2 were PM100117/18 derivatives retaining only 
the first sugar moiety, l-axenose (Fig.  4c). These results 
implicate the GTs GonG1 and GonG2 in transfer of 
the first and second 2,6DOH moiety, respectively, dur-
ing PM100117/18 biosynthesis. UPLC and HPLC/MS 
analysis of ΔgonG3 metabolite biosynthesis showed the 
production of derivative 5 (Fig.  4b) as well as an addi-
tional compound, 13 (UPLC Rt = 5.143 min, m/z 1471.8 
[M + Na]+), with absorption (254 nm) and mass spectra 
compatible with a PM100118 derivative lacking the third 
sugar moiety. Confirmation of this structure by NMR 
analysis (Fig. 4c; Additional file 2) endorsed the involve-
ment of the GT GonG3 in transfer of the third 2,6DOH, 
l-rhodinose. Lastly, deletion of gonG4 did not show any 
effect either on PM100117/18 biosynthesis, which were 
produced at comparable levels to those observed in the 
wild type strain S. caniferus GUA-06-05-006A, or on 
the accumulation of novel PM100117/18 derivatives 
(Fig. 4a, b). The study of the possible role of this gene in 
PM100117/18 biosynthesis is addressed in section below.
We conducted a series of experiments to investigate 
the possible functional role of the putative GT GonG4. 
Firstly, a precise quantification of PM100117/18 produc-
tion in strain ΔgonG4 and wild type S. caniferus GUA-06-
05-006A confirmed that gonG4 deletion has no impact on 
the production level of these compounds, suggesting that 
putative GT GonG4 might not be involved in their bio-
synthesis (Fig.  5a). To assess the potential of GonG4 to 
transfer 2,6DOHs to PM100117/18, we increased its pres-
ence in S. caniferus GUA-06-05-006A by over-expressing 
gonG4 using the integrative plasmid pSGonG4. Precise 
UPLC-based quantification of PM100117/18 produc-
tion in the resultant strain, OEgonG4, did not show any 
change with respect to the wild type strain (Fig. 5b; Addi-
tional file  3: Fig. S3a). Next, we reasoned that, under 
certain conditions, transfer of 2-deoxy-l-fucose and 
l-rhodinose as second 2,6DOH units to form PM100117 
and PM100118, respectively, might involve two differ-
ent GTs. However no potential derivative containing 
the second sugar moiety was detected when gonG4 was 
over-expressed in ΔgonG2 (Additional file  3: Fig. S3b). 
On the other hand, a defensive function consisting of 
ca b
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Fig. 4 Production of PM100117 (1) and PM100118 (2) biosynthesis intermediates 10–13 in glycosyltransferase gene mutant strains. UPLC analysis at 
254 (a) and 216 nm (b) wavelength of metabolite production in S. caniferus GUA-06-05-006A wild-type and ΔgonG1, ΔgonG2, ΔgonG3and ΔgonG4 
deletion mutants. NR: peak non-related to PM100117/18. c Chemical structure of various PM100117/18 analogues
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transferring of glucose units to antibiotic agents, which 
as a result become inactivated, has been proposed for 
several GTs [33–35]. Notwithstanding, the involvement 
of GonG4 in PM100117/18 inactivation by glycosylation 
has not been proven by experiments consisting of gonG4 
over-expression and subsequent feeding with PM100118. 
Therefore, the role of gonG4 on PM100117/18, if any, 
remains elusive.
In vitro cytotoxicity analysis of PM100117 and PM100118 
derivatives
We assessed the in  vitro cytotoxic activity of the novel 
analogues generated against cancer cell lines A549 
(human lung carcinoma cells), PSN1 (pancreas carci-
noma), MDA-MB-231 (human breast adenocarcinoma) 
and HT29 (human colorectal carcinoma). The GI50 (50% 
inhibition on cell growth) and TGI (total growth inhibi-
tion) concentrations of compounds 3 and 4 increased 
slightly with respect to PM100117/18, indicating a drop 
in the antitumor activity of the derivatives relative to the 
parental products (Table  1). The remaining novel prod-
ucts, 5-13, showed a more remarkable antitumor activity 
reduction, showing GI50 concentrations up to ten times 
higher than the natural compounds.
Discussion
Up to thirteen ORFs from the PM100117 and PM100118 
biosynthesis gene cluster can reliably be predicted to 
code for enzymes potentially involved in glycosylation 
reactions. Although bioinformatics analysis of the entire 
PM100117/18 gene cluster was previously addressed 
[32], here we provide additional in silico data support-
ing function assignment to putative DOH biosynthesis 
and GT enzymes (Additional file  1). The biosynthesis 
pathways of the PM100117/18 2,6DOHs moieties (Fig. 2) 
that can be deduced from these functions are congruent 
with 2,6DOHs biosynthesis reaction schemes previously 
reported [36]. Only a gene coding for an EryBII-type 
3-ketoreductase (3KR, Fig. 2) presumably involved in the 
formation of a NDP-4-keto-2,6DOH intermediate with 
an axial hydroxyl group at C3 has not been located within 
the gene cluster. The absence of functions required for 
2,6DOHs biosynthesis has been also described in the 
sequence analysis of the gene cluster of other glycosylated 
NPs, such as spinosyn [37], brasilicardin A [38] or mith-
ramycin [39]. However, in the later example, gene mtmC 
has been shown to code for a ketoreductase/methyltras-
nferase bifunctional enzyme [40, 41]. Thus, 3-C-meth-
yltransferase GonCM might be also responsible for the 
3-ketoreduction reaction leading to l-axenose. Alterna-
tively, methylation of the NDP-4-keto-2,6-dideoxyl-d-
Glucose intermediate by GonCM could be sequential to 
GonR3 activity (Fig.  2). Furthermore, the involvement 
of 3-C-methyltransferase GonCM and 3-dehydratase 
GonD3 in reaction steps of l-axenose and l-rhodinose 
biosynthesis, respectively, is also supported by genetic 
engineering experiments (Fig.  3). Likewise, implication 
of 3,5-epimerase GonE in PM100117/18 biosynthesis 
has been also confirmed. Nevertheless, putative isomer-
ase activity of this enzyme has not been further verified 
because of the impossibility to conduct NMR analysis 
of compounds 8 and 9. It is noteworthy the presence in 
the PM100117/18 gene cluster of two genes, gonR1 and 
gonR2, coding for putative 4-ketoreductase enzymes. 
However, the involvement of these enzymes in the bio-
synthesis of the three PM100117/18 DOH moieties has 
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Fig. 5 Analysis of GonG4 functional role on PM100117 and PM100118 biosynthesis. a Determination of PM100117/18 UPLC peak areas in strains 
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not been fully demonstrated by genetic experiments. 
The inactivation of gonR1 has no apparent effect on 
PM100117/18 biosynthesis, and its lack could be com-
plemented by the presence of an additional 4-ketoreduc-
tase encoded in S. caniferus chromosome, being gonR2 a 
good candidate. On the other hand, the impossibility of 
producing a gonR2 deletion mutant suggests the involve-
ment of this gene in important primary processes such 
as, for example, supply of essential sugars for cell-wall 
formation. A similar connection of primary and second-
ary metabolism via DOH biosynthesis genes has been 
previously reported for the biosynthesis of l-rhamnose 
required for spinosyn A production in Saccharopolyspora 
spinosa [42].
Gene deletion experiments have also enabled the 
identification of GTs responsible for transfer of each 
2,6DOH sugar moiety to its corresponding position of 
the PM100117/18 glycosylation pattern. Putative GT 
GonG1 is involved in transfer of the first sugar unit, 
l-axenose, since upon deletion of gonG1 no glycosylated 
PM100117/18 derivatives were produced (Fig. 4). Follow-
ing l-axenose transfer, GonG2 is responsible for the intro-
duction of the second sugar moiety, 2-deoxy-l-fucose and 
l-rhodinose, to PM100117 and PM100118 biosynthesis, 
respectively. Since two different 2,6DOH moieties can be 
transferred as second sugar unit, we previously predicted 
the involvement in this step of two GTs, each dedicated to 
transfer only one 2,6DOH. Nevertheless, UPLC and MS 
analysis did not detect production in ΔgonG2 strain of 
PM100117/18 analogues carrying the second DOH unit 
(Fig. 4), thus pointing at GonG2 as the only GT responsi-
ble for the introduction of both 2,6DOHs at second posi-
tion of the PM100117/18 glycosylation pattern. Finally, 
the structure of analogues derived from ΔgonG3 (Fig. 4c), 
which lack the third sugar moiety, suggests that GonG3 is 
the GT in charge of transferring l-rhodinose to the naph-
thoquinone moiety of the PM100117/18 glycosylation 
profile. Surprisingly, the functional role of the putative 
Table 1 In vitro cytotoxic activity of compounds 1–13
a These compounds were assayed individually
GI50 compound concentration that produces 50% inhibition on cell growth as compared to control cells, TGI compound concentration that produces total growth 
inhibition as compared to control cells, LC50 compound concentration that produces 50% cell death as compared to control cells, nd values not determined
Compound A549 (μM) HT29 (μM) MDA‑MB‑231 (μM) PSN1 (μM)
1
PM100117
GI50 1.52 3.04 2.66 nd
TGI 1.84 3.23 2.79 nd
LC50 2.22 3.61 2.97 nd
2
PM100118
GI50 2.24 1.92 1.73 nd
TGI 3.13 2.81 2.75 nd
LC50 4.28 4.09 4.16 nd
3
From mutant ΔgonCM
GI50 1.94 5.03 4.06 2.97
TGI 2.39 6.07 6.39 3.23
LC50 3.16 >6.45 >6.45 >6.45
4
From mutant ΔgonCM
GI50 2.02 5.22 4.39 3.13
TGI 2.58 6.76 5.78 3.41
LC50 >6.97 >6.97 >6.76 >6.97
5
From mutant ΔgonD3
GI50 >6.82 >6.82 >6.82 >6.82
TGI nd nd nd nd
LC50 nd nd nd nd
6, 7, 8 and 9
From mutant ΔgonEa
GI50 >10.70 >10.70 >10.70 >10.70
TGI nd nd nd nd
LC50 nd nd nd nd
10
From mutant ΔgonG1
GI50 >10.70 >10.70 >10.70 >10.70
TGI nd nd nd nd
LC50 nd nd nd nd
11 and 12
From mutant ΔgonG2a
GI50 >9.20 >9.20 >9.20 >9.20
TGI nd nd nd nd
LC50 nd nd nd nd
13
From mutant ΔgonG3
GI50 >6.90 >6.90 >6.90 >6.90
TGI nd nd nd nd
LC50 nd nd nd nd
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GT GonG4 remains elusive. As a primary hypothesis, 
we speculated a role for GonG4 on transferring 2-deoxy-
l-fucose or l-rhodinose as second sugar moiety. How-
ever, neither PM100117 nor PM100118 production was 
detected upon gonG4 over-expression in ΔgonG2 mutant 
strain (Fig.  5d). Alternatively, GonG4 might be inactive, 
but sequence alignment with functional glycosyltrans-
ferases did not reveal obvious differences supporting that 
possibility, or require post-translational regulatory signals 
for its activation. Moreover, it seems plausible also to con-
template that under certain environmental conditions, 
GonG4 might have a role on transferring 2,6DOH moie-
ties other than l-axenose, 2-deoxy-l-fucose or l-rhod-
inose, leading to the production of natural PM100117/18 
derivatives. This is consistent with the presence in the 
PM100117/18 gene cluster of two ORFs, gonR1 and 
gonR2, coding for putative 4-ketoreductase enzymes. 
Their presence in the cluster allows us to speculate with 
the biosynthesis of additional 2,6DOHs. For instance, 
last step of 2-deoxy-l-fucose an l-rhodinose biosynthesis 
could be branched towards the formation of l-olivose and 
l-amicetose, respectively, if either GonR1 or GonR2 were 
able to produce hydroxyl groups in equatorial configura-
tion at C4. However, based on sequence analysis data, it is 
not possible to forecast the resulting stereo configuration 
after GonR1 and/or GonR2 activity. Otherwise, we cannot 
rule out the biosynthesis of other 2,6DOHs by the activ-
ity of enzymes encoded in other locations of S. caniferus 
chromosome.
Standing by the chemical structure of PM100117/18 
analogues produced by the mutant strains analyzed 
in this work, we can make interesting conclusions on 
the substrate flexibility of GonG1, GonG2 and GonG3. 
When genes coding for these putative GTs are indi-
vidually deleted, none of the two remaining GTs is flex-
ible to catalyze the transfer of its own natural sugar to 
the acceptor aglycone. This apparently low promiscuity 
of the three GTs towards the acceptor substrate con-
trasts with the flexibility showed by GonG1 to transfer 
l-rhodinose (compounds 3 and 4) as first sugar moi-
ety to the PM100117/18 polyketide ring (Fig.  3) in the 
ΔgonCM mutant, in which l-axenose biosynthesis is 
presumably suppressed. Another interesting observa-
tion from the structure of the compounds detected in 
mutants ΔgonCM and ΔgonG2 is the production of a 
derivative with a hydroxyl functional group at C18 of 
the PM100117/18 macrolactone ring (compounds 3 and 
11), a feature also observed in the polyketide skeleton 
of the structurally related antibiotic brasilinolide A [43]. 
This seems to reinforce the structural and biosynthetic 
relationships between both compounds. On the other 
hand, accumulation of the naphthoquinone moiety (com-
pound 6) is exclusively detected in strain ΔgonE, and not 
in other mutant strains, such as ΔgonG1 or ΔgonG2, in 
which this chromophore is neither incorporated into the 
PM100117/18 structure (Figs. 3, 4). Based on our current 
knowledge on PM100117/18 biosynthesis, no suitable 
explanation to this observation can be exposed. Moreo-
ver, the naphthoquinone chromophore and its deriva-
tive compound 7 do not show in vitro cytotoxic activity 
(Table 1), in spite of the structural and biosynthetic con-
nection of these products to menaquinone, whose anti-
tumor properties have been repeatedly noted [44, 45]. 
Furthermore, as it was predictable from a previous report 
[32], removal of large portions from PM100117/18 struc-
ture, as displayed in different degrees by compounds 5, 
10, 11, 12 and 13, resulted in a remarkable decrease of 
in  vitro cytotoxicity. Only compounds 3 and 4, which 
preserve chemical structures containing three 2,6DOHs, 
retain activity levels comparable to those showed by the 
parental products (Table 1).
Given their biological activity, PM100117/18 constitute 
appealing potential targets of biochemical, genetic and 
medical research. Findings on PM100117/18 biosynthesis 
reported in this work will enable the manipulation of the 
described glycosylation machinery by genetic methods in 
order to generate additional structural diversity of these 
compounds.
Conclusions
PM100117 and PM100118 exhibit a composition of 
structural elements with biosynthetic interest, such as a 
naphthoquinone chromophore and three 2,6DOHs. Pre-
viously, we showed the vital role of the naphthoquinone 
unit on the PM100117/18 biological activity. Herein, 
the 2,6DOHs moieties are proven to be equally essen-
tial to PM100117/18 cytotoxicity. Therefore, manipu-
lations aimed to biosynthesize novel PM100117/18 
antitumor derivatives must contemplate the preserva-
tion of these structural components. In addition, we 
have demonstrated that PM100117/18 glycosylation can 
be genetically manipulated to direct the biosynthesis 
of novel derivatives. At least one GT coded within the 
PM100117/18 gene cluster has shown certain flexibility 
towards its natural 2,6DOH donor substrate, widening 
future perspectives to successfully fulfill the engineer-
ing of novel analogues by combinatorial biosynthesis 
methods. On the other hand, the uncertain functional 
role of the putative GT GonG4, and the presence in the 
PM100117/18 gene cluster of two ORFs coding for puta-
tive 4-ketoreductase enzymes, invites to speculate with 
the biosynthesis, under certain environmental condi-
tions, of additional natural products structurally related 
to PM100117/18. The role of these enzymes deserves fur-
ther investigations, which might require performance of 
biochemical and enzymatic analyses.
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Methods
Bacterial strains, media and culture conditions
The PM100117/18 producer S. caniferus GUA-06-05-
006A [31] and its isogenic strains were routinely culti-
vated on solid medium A [46] or in TSB [47] medium. 
Cultures for PM100117/18 production experiments 
were carried out in supplemented MS medium (SMS) 
[32] at 30  °C and rotary shaking at 200  rpm for 7  days. 
A more detailed description of these fermentations can 
be found in a previous report [32]. The Escherichia coli 
strains used for gene cloning (DH10B) [48] and interge-
neric conjugation (ET12567/pUB307) [47] were grown 
at 37 °C in 2xTY medium. All media were supplemented, 
when required, with the appropriate antibiotic for plas-
mid selection following standard directions [47].
Analysis of PM100117 and PM100118 production
Whole-culture samples (2 ml) from S. caniferus GUA-06-
05-006A wild type, or the corresponding mutant strains, 
were mixed with the same volume of ethyl acetate and 
shacked vigorously at room temperature for 1  h. The 
organic phase was collected and evaporated to dryness 
with a Speed-Vac. The residue was re-dissolved in 60 µl of 
methanol:DMSO (1:1), clarified by centrifugation and then 
subjected to UPLC and LC/MS analysis as described else-
where [49]. To assess the PM100117/18 production level, 
SMS medium was vacuum-filtrated with nitrocellulose 
filters of 0.45 µm pore size (Millipore). After 7-days culti-
vation of the respective strains in clarified SMS medium, 
2-ml whole-culture samples were collected by triplicate 
and centrifuged. The cell pellet was washed twice with mil-
liQ water and then incubated for 72 h at 100 °C to deter-
mine cell dry-weight of the culture. Metabolite extraction 
and UPLC analysis were performed as mentioned above. 
The final sample solution was appropriately diluted to 
ensure reliable linear-range PM100117/18 quantifications. 
Peak areas were determined by triplicate and normalized 
with respect to the corresponding dry-weight values.
Purification of PM100117 and PM100118 derivatives
For purification of compounds 3–13, cultures of the corre-
sponding producing strains were centrifuged and the super-
natants were filtered and applied to a solid-phase extraction 
cartridge (Sep-Pak Vac C18, 10  g, Waters). The retained 
material in each case was eluted with a mixture of metha-
nol and 0.05% TFA in water. A linear gradient from 0 to 
100% methanol in 60 min, at 10 ml/min, was used. Fractions 
were taken every 5 min and analyzed by UPLC. The frac-
tions containing the desired compounds were evaporated 
in vacuo and subsequently re-dissolved in a small volume 
of a mixture of DMSO and methanol (50:50). For purifica-
tion of compounds 6 and 7 the extracted broth was acidi-
fied by adding formic acid up to 1% and re-extracted with 
one volume of ethyl acetate. Additionally, purification of 
compounds 3 and 4, required extraction from cell pellets 
with ethyl acetate. The resulting pellet extracts were simi-
larly evaporated and re-dissolved. The compounds of inter-
est were purified by preparative HPLC using a SunFire C18 
column (10 µm, 10 × 250 mm, Waters). Compounds were 
chromatographed with mixtures of acetonitrile or methanol 
and 0.05% TFA in water in isocratic conditions optimized 
for each peak, at 7 ml/min, and when needed (compounds 
3, 4, 6 and 7) collected on 0.1 M phosphate buffer, pH 7.0. 
After every purification step, the collected compounds were 
diluted fourfold with water and then applied to a solid-
phase extraction cartridge (Sep-Pak C18, Waters). The car-
tridge was washed with water, the retained compound was 
eluted with methanol and dried in vacuo. Once the purifica-
tion was finished, the compounds were dissolved in a mix-
ture of tert-butanol and water (1:1) and lyophilized.
In vitro cytotoxicity assay
The procedure to determine the in vitro antitumor activ-
ity of the PM100117/18 analogues obtained in this work 
was previously described [31, 32].
DNA manipulation and plasmids construction
DNA manipulation experiments in Escherichia coli and S. 
caniferus GUA-06-05-006A were carried out according 
to standard protocols [47, 50]. PCR amplifications were 
performed by using Herculase II Fusion polymerase (Agi-
lent Technologies) with the touchdown PCR procedure 
previously reported [32]. Primers and plasmids used in 
this work are described in (Additional file 4: Table S6). To 
accomplish single deletion of genes gonCM, gonD3, gonE, 
gonR1, gonR2, gonG1, gonG2, gonG3 and gonG4, the down-
stream DNA sequence of the corresponding target ORFs 
were amplified with the primer pairs EcoRV-CM/NdeI-
CM, EcoRV-D3/BamHI-D3, EcoRV-E/BamHI-E, 
BamHI-R1/EcoRV-R1, EcoRV-R2/BamHI-R2, BamHI-
G1/EcoRV-G1, BglII-G2/EcoRV-G2, NdeI-G3/EcoRV-
G3 and BamHI-G4/EcoRV-G4, respectively, and cloned 
in the designated restriction sites (bold) of plasmid pEFBA-
oriT [51], downstream to the aac(3)IV gene, which con-
fers resistance to apramycin (ApmR). Then, the upstream 
sequence of the cited target genes were likewise amplified 
with the primer pairs NsiI-CM/SpeI-CM, NsiI-D3/SpeI-
D3, NsiI-E/SpeI-E, SpeI-R1/NsiI-R1, NsiI-R2/SpeI-R2, 
SpeI-G1/NsiI-G1, SpeI-G2/NsiI-G2, XbaI-G3/NsiI-G3 
and SpeI-G4/NsiI-G4, respectively, and cloned upstream 
to the aac(3)IV gene. Finally, the hygromycin B resist-
ance (HygR) gene marker, hyg, was extracted by XbaI/NheI 
digestion from plasmid pLHyg [52] and introduced in the 
XbaI site of the deletion plasmids. Gene hyg allows recog-
nizing clones in which a complete gene replacement by a 
double cross-over has taken place (HygS ApmR) from those 
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in which a single cross-over event has integrated the dele-
tion plasmid into the chromosome (HygR ApmR). To con-
struct the pSETH plasmid backbone, used to achieve gene 
complementation and over-expression experiments, a 1.6-
kb DNA fragment was amplified from plasmid pDR4 [53] 
with the primer pair NcoI-dHGR/NcoI-rvHGR and cloned 
in the NcoI site of plasmid pSETec [49], which harbors 
the constitutive ermE*p promoter. Plasmids intended to 
accomplish gene complementation and over-expression 
were constructed by inserting the respective target ORF in 
the BamHI/EcoRV sites of pSETH (Additional file 4: Table 
S6). Correct fragment insertion in deletion and comple-
mentation plasmids was verified by PCR and sequencing.
Gene mutation and complementation by intergeneric 
conjugation
Deletion plasmids pDgonCM, pDgonD3, pDgonE, 
pDgonR1, pDgonG1, pDgonG2, pDgonG3 and pDgonG4 
(Table S6) were introduced in S. caniferus GUA-06-05-
006A by intergeneric conjugation [32] to generate dele-
tion strains ΔgonCM, ΔgonD3, ΔgonE, ΔgonR1, ΔgonG1, 
ΔgonG2, ΔgonG3 and ΔgonG4, respectively. ORF replace-
ment in the resulting mutant strains was confirmed by 
PCR (Additional file 4: Fig. S5) with the primer pairs indi-
cated in Table S6 (Additional file 4: Table S6). Complemen-
tation plasmids pCgonCM, pCgonD3, pCgonE, pCgonG1, 
pCgonG2 and pCgonG3 were then introduced by the 
same procedure in the corresponding mutant strains to 
afford strains CgonCM, CgonD3, CgonE, CgonG1, CgonG2, 
CgonG3, in which PM100117/18 biosynthesis was par-
tially restored (Additional file 5: Fig S6). Plasmids, pSETH, 
pCgonR2 and pCgonG4 were also transferred to S. cani-
ferus GUA-06-05-006A to produce strains GUA-pSETH, 
OEgonR2 and OEgonG4, respectively. On the other hand, 
transfer of pSETH and pCgonG4 to mutant ΔgonG2 
yielded strains ΔG2-pSETH and ΔG2-OEG4, respectively. 
The exconjugant selection procedure followed in this work 
was thoroughly described in a previous report [31].
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